EP
NAUT icon

Essential Partners’s Nautilus Biotechnolgy NAUT Stock Holding History

Essential Partners’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23
Closed -$17 – 2744
2025
Q2 		$17 Buy
+23
New +$17 ﹤0.01% 2234

Other funds holding NAUT

AH Capital Management
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Amazon.com Inc
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Essential Partners's NAUT Position: Q3 2025 in Review

Essential Partners sold out of Nautilus Biotechnolgy (NAUT) in Q3 2025, closing a stake of 23 shares — an estimated $17 sold.

Essential Partners first reported a position in NAUT in Q2 2025 and held it in 1 quarter. The position peaked at $17 in Q2 2025. 68 funds tracked by Wall St. Rank hold NAUT as of Q3 2025.

  • Essential Partners reported no remaining Nautilus Biotechnolgy position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 23 Nautilus Biotechnolgy shares in Q3 2025, an estimated $17.
  • Essential Partners first reported a position in Nautilus Biotechnolgy in Q2 2025 and held it in 1 quarter.
  • Essential Partners's Nautilus Biotechnolgy position peaked at $17 in Q2 2025.
  • 68 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.